These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23657383)

  • 21. US credit crunch impacts biotech across the globe.
    Mitchell P
    Nat Biotechnol; 2008 Apr; 26(4):359-60. PubMed ID: 18391997
    [No Abstract]   [Full Text] [Related]  

  • 22. European markets target foreign biotechs.
    Louët S
    Nat Biotechnol; 2003 Jul; 21(7):719. PubMed ID: 12833075
    [No Abstract]   [Full Text] [Related]  

  • 23. Keeping it real with investors.
    Dipp M; Westphal C; Mirkin C; Baker J; Harper T; Harris C
    Nat Biotechnol; 2006 Feb; 24(2):133-5. PubMed ID: 16526102
    [No Abstract]   [Full Text] [Related]  

  • 24. 2007--a banner year for biotech.
    Lawrence S
    Nat Biotechnol; 2008 Feb; 26(2):150. PubMed ID: 18259162
    [No Abstract]   [Full Text] [Related]  

  • 25. Public biotech 2010--the numbers.
    Huggett B; Hodgson J; Lähteenmäki R
    Nat Biotechnol; 2011 Jul; 29(7):585-91. PubMed ID: 21747381
    [No Abstract]   [Full Text] [Related]  

  • 26. When your stock takes a nosedive.
    Jacobs T
    Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
    [No Abstract]   [Full Text] [Related]  

  • 27. The responsibilities of growing up.
    Nat Biotechnol; 2006 Mar; 24(3):225. PubMed ID: 16525362
    [No Abstract]   [Full Text] [Related]  

  • 28. Hedge funds gain edge by doubling biotech investments.
    Ransom J
    Nat Biotechnol; 2006 Apr; 24(4):373-4. PubMed ID: 16601707
    [No Abstract]   [Full Text] [Related]  

  • 29. Capital faucet wide-open. Firms' healthcare-related investments up 16% in first half.
    Pallarito K
    Mod Healthc; 1997 Sep; 27(35):76. PubMed ID: 10170390
    [No Abstract]   [Full Text] [Related]  

  • 30. Biotech's wellspring: the health of private biotech in 2012.
    Huggett B
    Nat Biotechnol; 2013 May; 31(5):396-403. PubMed ID: 23657390
    [No Abstract]   [Full Text] [Related]  

  • 31. My worst biotech investment.
    Jacobs T
    Nat Biotechnol; 2006 Apr; 24(4):401. PubMed ID: 16601718
    [No Abstract]   [Full Text] [Related]  

  • 32. Another clue to biotech value.
    Jacobs T
    Nat Biotechnol; 2003 Jul; 21(7):746. PubMed ID: 12833091
    [No Abstract]   [Full Text] [Related]  

  • 33. Companies jostle for access to public markets.
    Bouchie A
    Nat Biotechnol; 2003 Dec; 21(12):1413-4. PubMed ID: 14647309
    [No Abstract]   [Full Text] [Related]  

  • 34. Other ways of financing your company.
    Aldag J; Kessel M; Ibrahim A; Hill R; McCubbin P
    Nat Biotechnol; 2008 Feb; 26(2):155-7. PubMed ID: 18273945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IPOs: the narrow window closes?
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1489. PubMed ID: 15583641
    [No Abstract]   [Full Text] [Related]  

  • 36. Biotech IPOs: handle with care.
    Jacobs T
    Nat Biotechnol; 2003 Dec; 21(12):1437. PubMed ID: 14647322
    [No Abstract]   [Full Text] [Related]  

  • 37. Biotechs for pennies?
    Jacobs T
    Nat Biotechnol; 2004 Dec; 22(12):1509. PubMed ID: 15583652
    [No Abstract]   [Full Text] [Related]  

  • 38. Biotech IPOs--flop or pop?
    Jacobs T
    Nat Biotechnol; 2004 Aug; 22(8):949. PubMed ID: 15286641
    [No Abstract]   [Full Text] [Related]  

  • 39. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 40. Looking at US versus European exit opportunities.
    Lawrence S
    Nat Biotechnol; 2005 Oct; 23(10):1203. PubMed ID: 16302294
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.